Lynne Krummen, Ph.D. 

Executive Vice President, Product Development 

Lynne Krummen, Ph.D., has served as Vir’s Executive Vice President, Product Development since October 2023. She joined Vir in 2018. During her time at Vir, she has focused on ensuring the timely progress of our critical clinical pipeline programs, including the accelerated authorization of sotrovimab for in treating individuals at high risk of severe complications from COVID-19.

Before joining Vir, Dr. Krummen held a variety of leadership positions of increasing responsibility at Genentech, Inc., most recently as Vice President of Technical Development from 2016-2018. Prior to that, she was Vice President and Roche Global Head of Biologics, Regulatory Chemistry, Manufacturing and Controls (CMC). Before that, she held various leadership positions at Genentech, Inc. in Product Development, CMC Regulatory, Process Development Operations and Cell Culture Development.

Dr. Krummen received her Ph.D. in Endocrinology from the University of Cincinnati College of Medicine.